Royalty Pharma (RPRX) Short-term Investments (2020 - 2026)

Royalty Pharma has disclosed Short-term Investments across 7 years of filings, most recently posting $21.9 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $21.9 million, up 80.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.9 million (up 80.99% YoY), and the FY2025 annual result was $18.8 million, down 67.7% from the prior year.
• Short-term Investments came in at $21.9 million for Q1 2026 at Royalty Pharma, up from $18.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $409.3 million in Q3 2022 to a low of $1.3 million in Q4 2022.
• The 5-year median for Short-term Investments is $18.8 million (2025), against an average of $66.3 million.
• Peak annual rise in Short-term Investments reached 1307.69% in 2023, while the deepest fall reached 98.71% in 2023.
• Royalty Pharma's Short-term Investments stood at $1.3 million in 2022, then jumped by 1307.69% to $18.3 million in 2023, then soared by 218.03% to $58.2 million in 2024, then tumbled by 67.7% to $18.8 million in 2025, then rose by 16.49% to $21.9 million in 2026.
• The last three Short-term Investments figures came in at $21.9 million (Q1 2026), $18.8 million (Q4 2025), and $16.1 million (Q3 2025), per Business Quant data.